83 related articles for article (PubMed ID: 7847827)
1. Expression of p53 tumor suppressor gene, oncoprotein c-erbB-2, cellular proliferation and differentiation in malignant and benign pancreatic lesions.
Jaskiewicz K; Krige JE; Thomson J
Anticancer Res; 1994; 14(5A):1919-22. PubMed ID: 7847827
[TBL] [Abstract][Full Text] [Related]
2. p53 gene mutants expression, cellular proliferation and differentiation in oesophageal carcinoma and non-cancerous epithelium.
Jaskiewicz K; De Groot KM
Anticancer Res; 1994; 14(1A):137-40. PubMed ID: 8166440
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical localization of metallothionein in human breast cancer in comparison with cathepsin D, stromelysin-1, CD44, extracellular matrix components, P53, Rb, C-erbB-2, EGFR, steroid receptor content and proliferation.
Ioachim E; Kamina S; Demou A; Kontostolis M; Lolis D; Agnantis NJ
Anticancer Res; 1999; 19(3A):2133-9. PubMed ID: 10470161
[TBL] [Abstract][Full Text] [Related]
4. The prognostic significance of epidermal growth factor receptor (EGFR), C-erbB-2, Ki-67 and PCNA expression in breast cancer.
Ioachim E; Kamina S; Athanassiadou S; Agnantis NJ
Anticancer Res; 1996; 16(5B):3141-7. PubMed ID: 8920782
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical expression of Bcl-2 protein in breast lesions: correlation with Bax, p53, Rb, C-erbB-2, EGFR and proliferation indices.
Ioachim EE; Malamou-Mitsi V; Kamina SA; Goussia AC; Agnantis NJ
Anticancer Res; 2000; 20(6B):4221-5. PubMed ID: 11205251
[TBL] [Abstract][Full Text] [Related]
6. Expression of bcl-2, c-erbB-2, p53, and p21 (waf1-cip1) protein in thyroid carcinomas.
Soda G; Antonaci A; Bosco D; Nardoni S; Melis M
J Exp Clin Cancer Res; 1999 Sep; 18(3):363-7. PubMed ID: 10606183
[TBL] [Abstract][Full Text] [Related]
7. p53, Ki-ras, and DNA ploidy in human pancreatic ductal adenocarcinomas.
Weyrer K; Feichtinger H; Haun M; Weiss G; Ofner D; Weger AR; Umlauft F; Grünewald K
Lab Invest; 1996 Jan; 74(1):279-89. PubMed ID: 8569192
[TBL] [Abstract][Full Text] [Related]
8. [Expression correlation of Ki67 to P53,VEGF,and C-erbB-2 genes in breast cancer and their clinical significances].
Li BJ; Zhu ZH; Wang JY; Hou JH; Zhao JM; Zhang PY; Yao GY; Wang X; Long H; Yang MT; Rong TH
Ai Zheng; 2004 Oct; 23(10):1176-9. PubMed ID: 15473930
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical co-expression of c-erbb-2/Neu oncoprotein, altered tumour suppressor (p53) protein, EGF-R and EMA in histological subtypes of infiltrating duct carcinoma of the breast.
Sharma BK; Ray A; Kaur S; Gupta S
Indian J Exp Biol; 1999 Mar; 37(3):223-7. PubMed ID: 10641149
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical study of genetic alterations in intraductal and invasive ductal tumors of the pancreas.
Islam HK; Fujioka Y; Tomidokoro T; Sugiura H; Takahashi T; Kondo S; Katoh H
Hepatogastroenterology; 2001; 48(39):879-83. PubMed ID: 11462947
[TBL] [Abstract][Full Text] [Related]
11. Bilharzial related, organ confined, muscle invasive bladder cancer: prognostic value of apoptosis markers, proliferation markers, p53, E-cadherin, epidermal growth factor receptor and c-erbB-2.
Haitel A; Posch B; El-Baz M; Mokhtar AA; Susani M; Ghoneim MA; Marberger M
J Urol; 2001 May; 165(5):1481-7. PubMed ID: 11342901
[TBL] [Abstract][Full Text] [Related]
12. Expression of c-erbB-2 oncogene and p53 tumor suppressor gene in benign and malignant breast tissue: correlation with proliferative activity and prognostic index.
Alexiev BA; Bassarova AV; Popovska SL; Popov AA; Christov CZ
Gen Diagn Pathol; 1997 Jun; 142(5-6):271-9. PubMed ID: 9228249
[TBL] [Abstract][Full Text] [Related]
13. Ki-ras codon 12 point mutation and p53 mutation in pancreatic diseases.
Yamaguchi K; Chijiiwa K; Noshiro H; Torata N; Kinoshita M; Tanaka M
Hepatogastroenterology; 1999; 46(28):2575-81. PubMed ID: 10522044
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical analysis of expression of molecular biologic factors in intraductal papillary-mucinous tumors of pancreas--diagnostic and biologic significance.
Islam HK; Fujioka Y; Tomidokoro T; Sugiura H; Takahashi T; Kondo S; Katoh H
Hepatogastroenterology; 1999; 46(28):2599-605. PubMed ID: 10522048
[TBL] [Abstract][Full Text] [Related]
15. Matrix metalloproteinase expression in human breast cancer: an immunohistochemical study including correlation with cathepsin D, type IV collagen, laminin, fibronectin, EGFR, c-erbB-2 oncoprotein, p53, steroid receptors status and proliferative indices.
Ioachim EE; Athanassiadou SE; Kamina S; Carassavoglou K; Agnantis NJ
Anticancer Res; 1998; 18(3A):1665-70. PubMed ID: 9673387
[TBL] [Abstract][Full Text] [Related]
16. Stable reintroduction of wild-type P53 (MTmp53ts) causes the induction of apoptosis and neuroendocrine-like differentiation in human ductal pancreatic carcinoma cells.
Lang D; Miknyoczki SJ; Huang L; Ruggeri BA
Oncogene; 1998 Mar; 16(12):1593-602. PubMed ID: 9569027
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of different members of the type 1 growth factor receptor family and their association with cell proliferation in periampullary carcinoma.
Vaidya P; Kawarada Y; Higashiguchi T; Yoshida T; Sakakura T; Yatani R
J Pathol; 1996 Feb; 178(2):140-5. PubMed ID: 8683379
[TBL] [Abstract][Full Text] [Related]
18. Atypical alveolar hyperplasia: relationship with pulmonary adenocarcinoma, p53, and c-erbB-2 expression.
Kerr KM; Carey FA; King G; Lamb D
J Pathol; 1994 Dec; 174(4):249-56. PubMed ID: 7884586
[TBL] [Abstract][Full Text] [Related]
19. Correlations of morphology, proliferation indices, and oncogene activation in ductal breast carcinoma: nuclear grade, S-phase, proliferating cell nuclear antigen, p53, epidermal growth factor receptor, and c-erb-B-2.
Dabbs DJ
Mod Pathol; 1995 Aug; 8(6):637-42. PubMed ID: 8532697
[TBL] [Abstract][Full Text] [Related]
20. [Morphologic, morphometric and immunohistochemical studies on pancreatic intraductal hyperplasia and infiltrating carcinoma].
Tomaszewska R
Folia Med Cracov; 1999; 40(1-2):101-41. PubMed ID: 10909469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
